Andrew J. Murtha
YOU?
Author Swipe
View article: Supplementary Table 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 3. Targeted cfDNA sequencing quality metrics.
View article: Supplementary Figure 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 1. Identification of ERBB2 mutations and copy number amplifications.
View article: Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 7. Allelic imbalance and clonality of oncogenic mutations detected in metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
View article: Supplementary Table 14 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 14 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 14. Agreement between ERBB2 genotype and HER2 IHC.
View article: Supplementary Table 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 6. Tissue tumor fraction estimation and ERBB2 alterations.
View article: Data from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Data from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Purpose:HER2 targeting is increasingly relevant in metastatic urothelial cancer (mUC) because of emerging antibody–drug conjugates, in which assessment of tumor HER2/ERBB2 status could aid interpretation of ongoing trials. We evalua…
View article: Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 9. Variance in HER2 IHC across urothelial cancer (UC) tumor tissue.
View article: Supplementary Figure 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 3 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 3. Breakage-fusion-bridge (BFB) events inferred from whole-genome sequencing of circulating tumor DNA.
View article: Supplementary Table 11 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 11 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 11. ERBB2 structural variants detected in whole-genome ctDNA sequencing.
View article: Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 4. Double minute (DM) inferred from whole-genome sequencing of circulating tumor DNA.
View article: Supplementary Table 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 5. Genome-wide copy-number-based ctDNA fraction estimation. List of samples showing the copy number based tumor fraction estimation.
View article: Supplementary Table 13 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 13 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 13. Cohort of ERBB2-altered mUC based on ctDNA. List of all cfDNA samples with ERBB2 alterations.
View article: Supplementary Table 10 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 10 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 10. Whole-genome cfDNA sequencing quality metrics.
View article: Supplementary Table 12 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 12 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 12. ERBB2 ecDNA detected in whole-genome ctDNA sequencing.
View article: Supplementary Table 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 4. Mutation-based ctDNA fraction estimation. List of samples showing the mutation used for tumor fraction estimation.
View article: Supplementary Table 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 9. ERBB2 structural variants detected by targeted cfDNA sequencing.
View article: Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 5. Genomic landscape from targeted circulating tumor DNA (ctDNA) sequencing of ERBB2-altered metastatic urothelial cancer (mUC).
View article: Supplementary Table 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 7. ERBB2 mutations detected in cfDNA.
View article: Supplementary Table 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 8. ERBB2 copy number in cfDNA.
View article: Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 6. Prognostic stratification of metastatic urothelial cancer (mUC) by ctDNA and tissue ERBB2/HER2 status and Eastern Cooperative Oncology Group (ECOG) performance status.
View article: Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 8. ERBB2 mutation dynamics across serial tissue and ctDNA samples.
View article: Supplementary Table 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 2. Tumor tissue cohort.
View article: Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Figure 2. Targeted and whole-genome sequencing (WGS) of metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
View article: Supplementary Table 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer Open
Supplementary Table 1. Cohort composition and mUC cfDNA samples.
View article: Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer Open
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratif…
View article: Figure S7 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Figure S7 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer Open
Supplementary Figure 7. Immunohistochemical staining of MSH2, MSH6, MLH1, and PMS2.
View article: Supplementary Methods from <i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
Supplementary Methods from <i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression Open
Supplementary Methods
View article: Tables S1 - S11 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Tables S1 - S11 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer Open
Supplementary Table 1: Somatic mutation count across all samples within meta-cohort. Counts of mutations in all ctDNA positive samples. 95th and 90th percentile are highlighted. Samples are named as a function of their relative mutation co…
View article: Figure S6 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Figure S6 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer Open
Supplementary Figure 6. Deleterious structural rearrangements detected in MSH2, MSH6, and MLH1.
View article: Figure S3 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Figure S3 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer Open
Supplementary Figure 3. Representative copy number profiles of samples harboring MSH2 and MSH6 deletions.